NCT01393522View on ClinicalTrials.gov

Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine

NACompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Chronic Migraine
Interventions
DRUG

Milnacipran

titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then taper down as appropriate for dose.

DRUG

Placebo

Placebo dosing schedule was Day 1-2, 1 tablet daily, Day 3-6 BID, Day 7-14 BID, Day 15 an on through day 90 BID and taper down

Trial Locations (2)

27405

Headache Wellness Center, Greensboro

63141

Mercy Health Research, St Louis

All Listed Sponsors
lead

Timothy Smith

OTHER

NCT01393522 - Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine | Biotech Hunter | Biotech Hunter